{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:59:42Z","timestamp":1784627982631,"version":"3.55.0"},"reference-count":20,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE:<\/jats:title><jats:p>To describe the design features, utilization, and outcomes of a protocol treating children with status asthmaticus with continuous albuterol in the inpatient setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>We performed a retrospective cohort analysis of children ages 2 to 18 treated in the non\u2013intensive care, inpatient setting on a standardized treatment protocol for status asthmaticus from July 2011 to June 2013. We assessed characteristics associated with continuous albuterol therapy and, for those treated, duration of therapy and the proportion who clinically deteriorated (ICU transfer or progression to enhanced respiratory support) or who were identified as having hypokalemia or an arrhythmia. Using multivariable logistic regression, we determined which factors were associated with clinical deterioration or prolonged (&amp;gt;24 hours) continuous albuterol.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Of 3003 children meeting study criteria, 1298 (43%) received continuous albuterol. Older age, black race, lower initial oxygen saturation, and higher initial age-standardized heart rate and respiratory rate were associated with initiation of continuous albuterol therapy (P &amp;lt; .001 for all). Median duration of therapy was 14.4 hours (interquartile range, 7.7, 24.6); 340 children (26%) experienced prolonged therapy. Seventy children (5%) experienced clinical deterioration, and 33 children (3%) had identified hypokalemia or arrhythmia. Comorbid pneumonia and emergency department administration of intravenous magnesium or subcutaneous terbutaline were associated with prolonged therapy and clinical deterioration.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>With appropriate support structures and care processes, continuous albuterol can be delivered effectively in the non-ICU, inpatient setting with low rates of adverse outcomes. Certain initial clinical characteristics may help identify patients needing more intensive therapy.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2014-0907","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T04:24:19Z","timestamp":1412051059000},"page":"e976-e982","source":"Crossref","is-referenced-by-count":35,"title":["Safety and Effectiveness of Continuous Aerosolized Albuterol in the Non\u2013Intensive Care Setting"],"prefix":"10.1542","volume":"134","author":[{"given":"Ch\u00e9n C.","family":"Kenyon","sequence":"first","affiliation":[{"name":"Divisions of General Pediatrics, Center for Pediatric Clinical Effectiveness, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Fieldston","sequence":"additional","affiliation":[{"name":"Divisions of General Pediatrics, Center for Pediatric Clinical Effectiveness, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqun","family":"Luan","sequence":"additional","affiliation":[{"name":"Divisions of General Pediatrics, Center for Pediatric Clinical Effectiveness, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Keren","sequence":"additional","affiliation":[{"name":"Divisions of General Pediatrics, Center for Pediatric Clinical Effectiveness, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Zorc","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine, The Children\u2019s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"2021120906513175000_B1"},{"issue":"6","key":"2021120906513175000_B2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3109\/02770903.2011.585411","article-title":"Factors associated with the development of severe asthma exacerbations in children.","volume":"48","author":"Sala","year":"2011","journal-title":"J Asthma"},{"issue":"4","key":"2021120906513175000_B3","first-page":"CD001115","article-title":"Continuous versus intermittent beta-agonists in the treatment of acute asthma.","author":"Camargo","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2021120906513175000_B4","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/00003246-199310000-00015","article-title":"A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children.","volume":"21","author":"Papo","year":"1993","journal-title":"Crit Care Med"},{"issue":"5","key":"2021120906513175000_B5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.113.5.1430","article-title":"Admission and discharge guidelines for the pediatric patient requiring intermediate care.","volume":"113","author":"Jaimovich","year":"2004","journal-title":"Pediatrics"},{"issue":"7\u20138","key":"2021120906513175000_B6","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1345\/aph.1A189","article-title":"Management of acute, severe asthma in children.","volume":"36","author":"Streetman","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2021120906513175000_B7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jemermed.2006.05.025","article-title":"A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma.","volume":"31","author":"Salo","year":"2006","journal-title":"J Emerg Med"},{"issue":"3","key":"2021120906513175000_B8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1081\/JAS-120018630","article-title":"Interrater agreement in the clinical evaluation of acute pediatric asthma.","volume":"40","author":"Stevens","year":"2003","journal-title":"J Asthma"},{"issue":"1 Pt 2","key":"2021120906513175000_B9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1542\/peds.106.S1.205","article-title":"Pediatric deaths attributable to complex chronic conditions: a population-based study of Washington State, 1980\u20131997.","volume":"106","author":"Feudtner","year":"2000","journal-title":"Pediatrics"},{"issue":"4","key":"2021120906513175000_B10","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2012-2443","article-title":"Development of heart and respiratory rate percentile curves for hospitalized children.","volume":"131","author":"Bonafide","year":"2013","journal-title":"Pediatrics"},{"issue":"4","key":"2021120906513175000_B11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/02770903.2012.757781","article-title":"Demographics, clinical course, and outcomes of children with status asthmaticus treated in a pediatric intensive care unit: 8-year review.","volume":"50","author":"Sheikh","year":"2013","journal-title":"J Asthma"},{"issue":"5","key":"2021120906513175000_B12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1155\/2005\/837645","article-title":"A systematic review of risk factors associated with near-fatal and fatal asthma.","volume":"12","author":"Alvarez","year":"2005","journal-title":"Can Respir J"},{"issue":"5","key":"2021120906513175000_B13","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1378\/chest.124.5.1880","article-title":"Profile of near-fatal asthma in an inner-city hospital.","volume":"124","author":"Dhuper","year":"2003","journal-title":"Chest"},{"issue":"1","key":"2021120906513175000_B14","first-page":"71","article-title":"Continuous nebulization for status asthmaticus.","volume":"69","author":"Portnoy","year":"1992","journal-title":"Ann Allergy"},{"issue":"2","key":"2021120906513175000_B15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpeds.2009.01.073","article-title":"High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial","volume":"155","author":"Andrews","year":"2009","journal-title":"J Pediatr"},{"issue":"2","key":"2021120906513175000_B16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PEC.0b013e3182809b48","article-title":"Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department.","volume":"29","author":"Krebs","year":"2013","journal-title":"Pediatr Emerg Care"},{"issue":"8","key":"2021120906513175000_B17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/thx.36.8.629","article-title":"Comparison of inhaled and intravenous terbutaline in acute severe asthma.","volume":"36","author":"Williams","year":"1981","journal-title":"Thorax"},{"issue":"6","key":"2021120906513175000_B18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1164\/ajrccm.149.6.8004299","article-title":"Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study.","volume":"149","author":"Salmeron","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2021120906513175000_B19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/(SICI)1099-0496(199703)23:3<184::AID-PPUL3>3.0.CO;2-O","article-title":"Hospitalization patterns in severe acute asthma in children.","volume":"23","author":"Schuh","year":"1997","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"2021120906513175000_B20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1081-1206(10)61444-5","article-title":"Rates and characteristics of intensive care unit admissions and intubations among asthma-related hospitalizations.","volume":"93","author":"Pendergraft","year":"2004","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/4\/e976\/1100438\/peds_2014-0907.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/4\/e976\/1100438\/peds_2014-0907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:05:26Z","timestamp":1650276326000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/134\/4\/e976\/32967\/Safety-and-Effectiveness-of-Continuous-Aerosolized"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-0907","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}